Neurological Biomarkers Market Size, Share, Growth Analysis, By Type(Genomic, Proteomic, Metabolomic, Imaging), By Application(Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder), By End User(Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations and Others), By Region - Industry Forecast 2024-2031

The largest piece in the global neurological biomarkers market share is held by North America. This growth is mainly due to the well-established healthcare and research infrastructure in the region. The United States and Canada houses major pharmaceutical and biotechnology companies which provides them a competitive advantage in the research & development for new neurological biomarkers. Moreover, the renowned medical device players involved in neurobiology are also contributing to the regional growth market. The market growth is also supported by the initiatives from government bodies providing grants and funding for different neuroscience projects. Various U.S. and Canadian universities and academic institutions are collaborating with industry to develop new biomarkers. 

Asia Pacific is witnessing the fastest growth in the market. Factors such as the rapidly increasing disposable income in developing nations like India & China and rising prevalence of neurological disorders are fuelling the growth of the market. Furthermore, increasing geriatric population who are very prone to these diseases, coupled with a growing incidence of the target disease is also projected to drive regional neurological biomarkers market growth. The regional market is also benefitting from increased advancements R&D conducted by leading companies. For example, in June 2022, scientists from Hiroshima University and Kobe University developed a new blood test to diagnose Parkinson's disease. Additionally, researchers had utilized an inhibition assay P450 to detect alterations in Parkinson's disease.